Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE W DEXTROSE 4 25 IN PLASTIC CONTAINER versus DIANEAL 137 W DEXTROSE 2 5 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: DIALYTE W DEXTROSE 4 25 IN PLASTIC CONTAINER versus DIANEAL 137 W DEXTROSE 2 5 IN PLASTIC CONTAINER.
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER vs DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intraperitoneal administration of dextrose creates an osmotic gradient that promotes ultrafiltration and removal of uremic toxins and excess fluid across the peritoneal membrane, while electrolytes in the solution correct imbalances.
Creates an osmotic gradient across the peritoneal membrane, facilitating ultrafiltration and diffusion of solutes (e.g., urea, creatinine, electrolytes) from blood into the dialysate, which is then drained.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day, via continuous ambulatory peritoneal dialysis (CAPD).
Intraperitoneal (IP) administration: 2 liters per exchange, 4 exchanges daily, with dwell time of 4-6 hours. Dextrose concentration (2.5%) selected based on ultrafiltration needs.
None Documented
None Documented
Not applicable (combination product); dextrose follows glucose kinetics (~1.5–2 h); electrolytes have no half-life.
Not applicable as a single entity; the dextrose component has a plasma half-life of approximately 15-20 minutes after absorption, reflecting rapid insulin-mediated clearance.
Primarily renal; glucose is reabsorbed or metabolized; electrolytes follow renal handling. Not applicable as a drug; dialysate components are removed via peritoneal dialysis effluent.
Primarily excreted via peritoneal dialysis fluid removal; glucose is metabolized systemically. Renal excretion negligible as dialysis solution is not absorbed significantly. Fecal excretion minimal.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution